developer_as

About developer_as

This author has not yet filled in any details.
So far developer_as has created 18 blog entries.

Arix Bioscience notes Artios Pharma’s new collaboration to develop inhibitors of novel cancer targets

LONDON, 12 June, 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or the “Company”), a global healthcare and life science company supporting medical innovation, is pleased to note the announcement by Artios Pharma Ltd, an Arix Bioscience Group Business, that it has signed a research collaboration and option agreement with Masaryk University (“MU”) in the Czech [...]

2017-06-12T09:30:41+00:00 June 12th, 2017|News Release|

Arix Bioscience notes the formation of Artios Pharma’s world-leading Scientific Advisory Board

Dr Simon Boulton – Senior Group Leader at the Francis Crick Institute and VP of Scientific Strategy at Artios Dr KJ Patel – tenured Principal Investigator at the Medical Research Council Laboratory of Molecular Biology at the University of Cambridge Dr Jos Jonkers – Professor of Molecular Experimental Oncogenetics and Cancer Therapeutics, and Head of Molecular Pathology at [...]

2017-06-08T09:52:48+00:00 June 8th, 2017|News Release|

Arix Bioscience to present at Jefferies 2017 Global Healthcare Conference in New York

LONDON, 31 May, 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or “the Company”), a global healthcare and life science company supporting medical innovation, today announces that Joe Anderson, Chief Executive Officer of Arix Bioscience, will present at the Jefferies 2017 Global Healthcare Conference to be held on 6-8 June in New York, US. The [...]

2017-05-31T22:52:10+00:00 May 31st, 2017|News Release|

Arix Bioscience co-leads $45 million Series B investment round for Harpoon Therapeutics

- Funding to advance two of Harpoon’s immuno-oncology programmes into clinical trials - LONDON, 25 May, 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or “the Company”), a global healthcare and life science company supporting medical innovation, today announced that Harpoon Therapeutics, a new Arix Group Business, has closed a Series B investment round raising [...]

2017-05-25T10:41:32+00:00 May 25th, 2017|News Release|

Arix Bioscience leads $65 million Series B investment round for Iterum

- Funding pivotal Phase 3 trial for novel antibiotic sulopenem - Investment in Ireland-based company focused on developing differentiated anti-infectives aimed at combatting pathogens LONDON, 19 May, 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or “the Company”), a global healthcare and life science company supporting medical innovation, today announced that Iterum, a new Arix [...]

2017-05-25T11:29:47+00:00 May 19th, 2017|News Release|

Arix Bioscience Notes Verona Pharma’s NASDAQ Global Market Listing and $80m Fundraise

LONDON, 28 April, 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or “the Company”), a global healthcare and life science company supporting medical innovation, is pleased to note the announcement by Verona Pharma plc, an Arix Bioscience Group Business, that it has raised approximately $80.0 million before expenses in a successful NASDAQ listing. Verona’s global [...]

2017-04-28T17:31:51+00:00 April 28th, 2017|News Release|

Maiden Annual Results 2016

London, UK, 28 April 2017: Arix Bioscience plc (LSE:ARIX) (“Arix Bioscience” or “the Company”), a global healthcare and life science company supporting medical innovation, today announces its maiden results for the period ended 31 December 2016. The following financial statements refer to the period in which Arix Bioscience was a private company, prior to its [...]

2017-04-28T10:19:04+00:00 April 28th, 2017|News Release|

US FDA authorisation for Verona Pharma to proceed with clinical investigation of RPL554 with the acceptance of investigational new drug application

LONDON, 18 April, 2017: Arix Bioscience plc (LSE:ARIX) (“Arix Bioscience” or “the Company”), a global healthcare and life science company supporting medical innovation, is pleased to note the announcement today by Verona Pharma, in which it has a 6.6% holding, that it has received authorisation from the Food and Drug Administration to proceed with the [...]

2017-04-18T13:39:37+00:00 April 18th, 2017|News Release|

Arix Bioscience plc, LDC and University of Leeds collaborate to develop novel therapeutics for metabolic diseases

First project from Arix’s agreement with LDC  LONDON, 20 MARCH 2017: Arix Bioscience plc (LSE:ARIX) (“Arix Bioscience” or “the Company”), a global healthcare and life science company supporting medical innovation, has signed an agreement with the Lead Discovery Center GmbH (LDC), Max Planck Innovation GmbH (MPI), and the University of Leeds to develop new therapeutics [...]

2017-03-20T11:09:35+00:00 March 20th, 2017|News Release|